Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
11
TCRX Quote, Financials, Valuation and Earnings
Last price:
$1.02
Seasonality move
:
-6.74%
Day range:
$1.00 - $1.05
52-week range:
$0.88 - $2.57
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.51x
P/B ratio:
0.46x
Volume:
672.9K
Avg. volume:
547.5K
1-year change:
-20.47%
Market cap:
$56.6M
Revenue:
$10.3M
EPS (TTM):
-$1.00
Analysts' Opinion
-
Consensus RatingTScan Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.00, TScan Therapeutics, Inc. has an estimated upside of 494.06% from its current price of $1.01.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing -- downside risk from its current price of $1.01.
Fair Value
-
According to the consensus of 5 analysts, TScan Therapeutics, Inc. has 494.06% upside to fair value with a price target of $6.00 per share.
TCRX vs. S&P 500
-
Over the past 5 trading days, TScan Therapeutics, Inc. has underperformed the S&P 500 by -3.25% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
TScan Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
TScan Therapeutics, Inc. has grown year-over-year revenues for 4 quarters straight. In the most recent quarter TScan Therapeutics, Inc. reported revenues of $2.6M.
Earnings Growth
-
TScan Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter TScan Therapeutics, Inc. reported earnings per share of -$0.18.
Enterprise value:
-797.4K
EV / Invested capital:
--
Price / LTM sales:
12.51x
EV / EBIT:
--
EV / Revenue:
-0.08x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.01x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$7.5M
Return On Assets:
-43.45%
Net Income Margin (TTM):
-1256.81%
Return On Equity:
-72.49%
Return On Invested Capital:
-47.16%
Operating Margin:
-929.41%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $21M | $2.8M | $10.3M | $665K | $2.6M | |
| Gross Profit | $15.7M | -$1.3M | $7.5M | -$46K | $1.8M | |
| Operating Income | -$93.5M | -$134.8M | -$135.8M | -$36.7M | -$23.9M | |
| EBITDA | -$88.1M | -$130.7M | -$132.9M | -$36M | -$23.1M | |
| Diluted EPS | -$2.09 | -$1.15 | -$1.00 | -$0.30 | -$0.18 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $165.7M | $124.1M | $194.2M | $292.7M | $157.2M | |
| Total Assets | $188.1M | $199.1M | $272.1M | $371.1M | $228.8M | |
| Current Liabilities | $21.3M | $17.3M | $29.8M | $36M | $18.7M | |
| Total Liabilities | $27.3M | $99.7M | $121.3M | $130.1M | $105.7M | |
| Total Equity | $160.8M | $99.4M | $150.9M | $241M | $123.1M | |
| Total Debt | $4.4M | $82.3M | $89.2M | $92.8M | $87M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$61.4M | -$110.8M | -$135.9M | -$27.4M | -$32M | |
| Cash From Investing | -$60.8M | -$52.6M | $109.4M | $27.3M | $14.8M | |
| Cash From Financing | $135.4M | $208.8M | $264K | $45.7M | $73K | |
| Free Cash Flow | -$64.5M | -$114.6M | -$140.3M | -$28.3M | -$32.2M | |
TCRX
Sector
Market Cap
$56.6M
$23.9M
Price % of 52-Week High
--
47.44%
Dividend Yield
0%
0%
Shareholder Yield
-1.79%
-1.9%
1-Year Price Total Return
-20.47%
-18.29%
Beta (5-Year)
--
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.01
200-day SMA
Sell
Level
$1.43
Bollinger Bands (100)
Sell
Level
0.97 - 1.13
Chaikin Money Flow
Sell
Level
-493.9K
20-day SMA
Sell
Level
$1.06
Relative Strength Index (RSI14)
Sell
Level
45.65
ADX Line
Sell
Level
34.74
Williams %R
Neutral
Level
-59.0909
50-day SMA
Sell
Level
$1.05
MACD (12, 26)
Buy
Level
0.26
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Sell
Level
-2.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.7197)
Sell
CA Score
(Annual)
Level (-2.0221)
Buy
Beneish M-Score
(Annual)
Level (-7.0672)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.3069)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, TCRX has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The TCRX average analyst price target in the past 3 months is $6.00.
-
Where Will TScan Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that TScan Therapeutics, Inc. share price will rise to $6.00 per share over the next 12 months.
-
What Do Analysts Say About TScan Therapeutics, Inc.?
Analysts are divided on their view about TScan Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that TScan Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is TScan Therapeutics, Inc.'s Price Target?
The price target for TScan Therapeutics, Inc. over the next 1-year time period is forecast to be $6.00 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is TCRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for TScan Therapeutics, Inc. is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TCRX?
You can purchase shares of TScan Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase TScan Therapeutics, Inc. shares.
-
What Is The TScan Therapeutics, Inc. Share Price Today?
TScan Therapeutics, Inc. was last trading at $1.02 per share. This represents the most recent stock quote for TScan Therapeutics, Inc.. Yesterday, TScan Therapeutics, Inc. closed at $1.01 per share.
-
How To Buy TScan Therapeutics, Inc. Stock Online?
In order to purchase TScan Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TCRX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TCRX
Sector
P/E ratio
--
21.37x
PEG ratio
--
-0.01x
P/B ratio
0.46x
1.72x
Price / LTM sales
12.51x
1.44x
Growth Metrics
TCRX
Sector
Revenue growth
286.02%
3.44%
Earnings growth
40.34%
14.97%
Revenue (5-year growth)
56.93%
6.27%
Earnings forecast
-$0.18
-$0.22
Profitability
TCRX
Sector
Profitability FY 2025
$7.5M
$2.4M
Return on invested capital
-47.16%
-33.43%
Return on assets
-43.45%
-29.45%
Return on equity
-72.49%
-40.29%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Apr
5
Estimated Next Earnings Date
Jul
5
Balance Sheet
TCRX
Sector
Total cash
$152.4M
$25.6M
Short term investments
$111.4M
$22.7M
Total assets
$244.6M
$70.4M
Long term debt
$87M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 4
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
